000282428 001__ 282428
000282428 005__ 20240229155040.0
000282428 0247_ $$2doi$$a10.1186/s12872-023-03469-4
000282428 0247_ $$2pmid$$apmid:37644408
000282428 037__ $$aDKFZ-2023-01755
000282428 041__ $$aEnglish
000282428 082__ $$a610
000282428 1001_ $$aRehm, Martin$$b0
000282428 245__ $$aMedical care and biomarker-based assessment of mortality in two cohorts of patients with chronic coronary syndrome 10 years apart.
000282428 260__ $$aLondon$$bBioMed Central$$c2023
000282428 3367_ $$2DRIVER$$aarticle
000282428 3367_ $$2DataCite$$aOutput Types/Journal article
000282428 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1693404467_15638
000282428 3367_ $$2BibTeX$$aARTICLE
000282428 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282428 3367_ $$00$$2EndNote$$aJournal Article
000282428 500__ $$a#LA:C070#
000282428 520__ $$aThis study aimed to describe the characteristics and mortality of two cohorts of patients with chronic coronary syndrome (CCS) recruited with identical study designs in the same rehabilitation clinics but approximately 10 years apart.The KAROLA cohorts included patients with CCS participating in an inpatient cardiac rehabilitation programme in Germany (KAROLA-I: years 1999/2000, KAROLA-II: 2009-2011). Blood samples and information on sociodemographic factors, lifestyle, and medical treatment were collected at baseline, at the end of rehabilitation, and after one year of follow-up. A biomarker-based risk model (ABC-CHD model) and Cox regression analysis were used to evaluate cardiovascular (CV) and non-CV mortality risk.We included 1130 patients from KAROLA-I (mean age 58.7 years, 84.4% men) and 860 from KAROLA-II (mean age 60.4 years, 83.4% men). Patients in the KAROLA-I cohort had significantly higher concentrations of CV biomarkers and fewer patients were taking CV medications, except for statins. The biomarker-based ABC-CHD model provided a higher estimate of CV death risk for patients in the KAROLA-I cohort (median 3-year risk, 3.8%) than for patients in the KAROLA-II cohort (median 3-year risk, 2.7%, p-value for difference < 0.001). After 10 years of follow-up, 91 (8.1%) patients in KAROLA-I and 45 (5.2%) in KAROLA-II had died from a CV event.Advances in disease management over the past 20 years may have led to modest improvements in pharmacological treatment during cardiac rehabilitation and long-term outpatient care for patients with CCS. However, modifiable risk factors such as obesity have increased in the more recent cohort and should be targeted to further improve the prognosis of these patients.
000282428 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000282428 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000282428 650_7 $$2Other$$aBiomarkers
000282428 650_7 $$2Other$$aCardiac rehabilitation
000282428 650_7 $$2Other$$aChronic coronary syndrome
000282428 650_7 $$2Other$$aMortality
000282428 650_7 $$2Other$$aPharmacological treatment
000282428 650_7 $$2Other$$aRisk factors
000282428 7001_ $$aJaensch, Andrea$$b1
000282428 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b2$$udkfz
000282428 7001_ $$0P:(DE-He78)1b59582b6c05ac4e57aa8b90dd9667f9$$aMons, Ute$$b3$$udkfz
000282428 7001_ $$aHahmann, Harry$$b4
000282428 7001_ $$aKoenig, Wolfgang$$b5
000282428 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b6$$udkfz
000282428 7001_ $$0P:(DE-HGF)0$$aRothenbacher, Dietrich$$b7$$eLast author
000282428 773__ $$0PERI:(DE-600)2059859-2$$a10.1186/s12872-023-03469-4$$gVol. 23, no. 1, p. 428$$n1$$p428$$tBMC cardiovascular disorders$$v23$$x1471-2261$$y2023
000282428 909CO $$ooai:inrepo02.dkfz.de:282428$$pVDB
000282428 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000282428 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1b59582b6c05ac4e57aa8b90dd9667f9$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000282428 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000282428 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000282428 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000282428 9141_ $$y2023
000282428 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-12
000282428 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-12
000282428 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-12
000282428 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-12
000282428 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CARDIOVASC DISOR : 2022$$d2023-08-25
000282428 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000282428 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000282428 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000282428 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T09:05:18Z
000282428 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T09:05:18Z
000282428 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2023-05-02T09:05:18Z
000282428 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000282428 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000282428 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000282428 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000282428 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000282428 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000282428 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000282428 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000282428 9201_ $$0I:(DE-He78)M050-20160331$$kM050$$lM050 Krebsprävention$$x3
000282428 980__ $$ajournal
000282428 980__ $$aVDB
000282428 980__ $$aI:(DE-He78)C070-20160331
000282428 980__ $$aI:(DE-He78)C120-20160331
000282428 980__ $$aI:(DE-He78)HD01-20160331
000282428 980__ $$aI:(DE-He78)M050-20160331
000282428 980__ $$aUNRESTRICTED